Oxeia Biopharmaceuticals, Inc.
StreetZero Signal 63
About Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. is a privately held clinical-stage biotech company headquartered in Boston, MA, developing OXE103, a ghrelin therapy for persistent concussion symptoms. The therapy demonstrated an 85% responder rate in Phase 2a clinical testing. The company is advancing to Phase 2b enrollment targeting 160 patients starting in 2026, with no approved treatments currently available for this condition.
LATEST FUNDINGCrowdfunding
$2.6M
Announced 2026-11-10
TOTAL RAISED$2.26M
IN THE NEWS
- 🔗 Oxeia Pioneering First Potential FDA-Approved Concussion Treatment, Launches Equity Crowdfunding Campaign to Fund Phase 2b Development
- 🔗 Oxeia Biopharmaceuticals, Inc.
- 🔗 Crowdfunding for Biotechs — Oxeia Biopharmaceuticals
- 🔗 /C O R R E C T I O N -- Oxeia Biopharmaceuticals, Inc./
- 🔗 Oxeia surpasses funding goal for concussion therapy - Drug Discovery World (DDW)
EMPLOYEES—
FOUNDED2014
HQBoston, MA, United States
Industry
Crowdfunding
Tags
BiotechClinical-stageCrowdfundingConcussion
Key highlights
- Launched equity crowdfunding on StartEngine to fund Phase 2b of OXE103.
- Phase 2a results showed 85% responder rate for persistent concussion symptoms.
- Oversubscribed raise surpassed $1.2M goal before close.
- Positioned as potential first FDA-approved concussion treatment.
Ask StreetZero about Oxeia Biopharmaceuticals, Inc.
Put our AI to work on this deal.
Similar companies
Other Crowdfunding deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account